ClinicalTrials.gg
Active, not recruitingNCT06883630Updated Mar 5, 2026

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

A Phase 1 interventional study of RC148 plus Carboplatin and Paclitaxel/pemetrexed and RC148 in Non-Small Cell Lung Cancer, sponsored by RemeGen Co., Ltd.. Active, not recruiting at 24 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by RemeGen Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 39 under way, 11 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
62nd of 250
121 · median 55
Started
2025
with 4 others
Phase 1
41 of 271
2 open now
Primary completion
2026-08
later than 13 of 38 live
Registered
262nd of 271
by date

Among the 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 62nd largest by enrollment of the 250 interventional ones that give a count, is one of 5 that started in 2025, is one of 41 in phase 1, reaches primary completion later than 13 of the 38 other live ones, and was the 262nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer

Read the detailed description

Primary objective: to evaluate the efficacy of RC148 injection as monotherapy or combination therapy in patients locally advanced or metastatic non-small cell lung cancer;

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the study and signed the ICF;
  2. Be willing to and able to act on the trial and the follow up procedures;
  3. Male or female, aged 18-80 years;
  4. Expected survival ≥ 3 months;
  5. PS score 0 or 1;
  6. All participants to be enrolled in cohorts 1-5 must be diagnosed with histopathologically or confirmed, unresectable locally advanced or NSCLC (stage IIIB//IIIC/IV according to the 8th edition of UICC/AJCC) and not amendable to curative surgery or radiation as assessed by investigator.

Exclusion criteria

Exclusion Criteria:

  1. Histopathologically or confirmed small cell lung cancer;
  2. Received major surgeries and still in recovery within 28 days before the first dose;
  3. Received any within 28 days prior to the first dose or plan to be vaccinated during the study (except for COVID-19 vaccine);
  4. Received (anti-PD-1/PD-L1/CTLA-4 antibody) or other immune checkpoint inhibitor treatment within 28 days prior to the first dose, or experienced prior permanent immunotherapy discontinuation due to immunotoxicity;
  5. Participated in other clinical trials and received other anti-tumor therapy within 28 days prior to the first dose;
  6. Poor compliance and unable to complete the study procedures as assessed by investigator;
  7. Have any other medical conditions, abnormal physical examinations or laboratory examinations that would be suspected interfere with participation or evaluation of the trial or increase the risk to the participant, in view of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    AGA-, NSCLC without systemic therapy

    Combination Therapy

    Drug: RC148 plus Carboplatin and Paclitaxel/pemetrexed

  • Experimental
    AGA-,PD-1+, NSCLC without systemic therapy

    Monotherapy

    Drug: RC148

  • Experimental
    EGFR mu, Non-squamous NSCLC after EGFR-TKIs treatment

    Combination Therapy

    Drug: RC148 plus Carboplatin and Paclitaxel/pemetrexed

Interventions

  • DrugRC148 plus Carboplatin and Paclitaxel/pemetrexed

    Drug pages: RC148 · Carboplatin · Paclitaxel · Pemetrexed

    RC148; Carboplatin; Paclitaxel; pemetrexed

    Also known as: RC148 Injection

  • DrugRC148

    RC148 Monotherapy

    Also known as: RC148 Injection

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Tumor assessment will be performed until radiographic disease progression, initiation of new anticancer therapy, withdrawal of consent, death, loss to follow-up, or other end of study criterion is met, whichever is earlier.

    Time frame: 24 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    Tumor assessment will be performed until radiographic disease progression, initiation of new anticancer therapy, withdrawal of consent, death, loss to follow-up, or other end of study criterion is met, whichever is earlier.

    Time frame: 24 months

  2. Duration of Response (DOR)

    Tumor assessment will be performed until radiographic disease progression, initiation of new anticancer therapy, withdrawal of consent, death, loss to follow-up, or other end of study criterion is met, whichever is earlier.

    Time frame: 24 months

  3. Progression-free survival (PFS)

    Tumor assessment will be performed until radiographic disease progression, initiation of new anticancer therapy, withdrawal of consent, death, loss to follow-up, or other end of study criterion is met, whichever is earlier.

    Time frame: 24 months

  4. Overall survival (OS)

    Tumor assessment will be performed until radiographic disease progression, initiation of new anticancer therapy, withdrawal of consent, death, loss to follow-up, or other end of study criterion is met, whichever is earlier.

    Time frame: 24 months

  5. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: 24 months

  6. Incidence of RC148 anti-drug antibody (ADA)

    Serum samples will be collected from participants for ADA analysis of RC148. The blood sampling time points and time windows are described in protocol

    Time frame: 24 months

  7. Maximum observed concentration (Cmax) of RC148

    Serum concentrations of RC148 in individual subjects at different time points after RC148 administration

    Time frame: 24 months

07

Study locations

24 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2026, 17 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 17 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 19, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Jul 31, 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06883630
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Mar 13, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

li zhang
study director · Sun Yat-sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: RC148 · Carboplatin · Paclitaxel · Pemetrexed

Start the discussion